Cargando…

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia

The majority of patients with newly diagnosed chronic myeloid leukemia (CML) will enjoy a life expectancy equivalent to that of unaffected individuals, but will remain on life-long treatment with a concomitant requirement for on-going hospital interactions for molecular monitoring and drug dispensin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Claudiani, Simone, Gatenby, Aoife, Szydlo, Richard, Nesr, George, Abulafia, Adi Shacham, Palanicawandar, Renuka, Nteliopoulos, Georgios, Khorashad, Jamshid, Foroni, Letizia, Apperley, Jane F., Milojkovic, Dragana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821602/ https://www.ncbi.nlm.nih.gov/pubmed/30923102 http://dx.doi.org/10.3324/haematol.2018.214809

Ejemplares similares

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
por: Nteliopoulos, Georgios, et al.
Publicado: (2019)

FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions
por: May, Philippa C., et al.
Publicado: (2023)

Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia
por: Claudiani, Simone, et al.
Publicado: (2020)

The UK SPIRIT 1 trial in newly-diagnosed chronic myeloid leukaemia (CML)
por: Gallipoli, Paolo, et al.
Publicado: (2022)

Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B
por: Bencomo-Alvarez, Alfonso E., et al.
Publicado: (2021)

Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies
por: Cook, Lucy B., et al.
Publicado: (2022)

Molecular techniques for the personalised management of patients with chronic myeloid leukaemia
por: Alikian, Mary, et al.
Publicado: (2017)

COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
por: Milojkovic, Dragana, et al.
Publicado: (2022)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
por: Claudiani, Simone, et al.
Publicado: (2021)

A retrospective observational research study to describe the real‐world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands
por: Claudiani, Simone, et al.
Publicado: (2022)

Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Innes, Andrew J., et al.
Publicado: (2021)

The role of ibrutinib in COVID-19 hyperinflammation: A case report
por: Maynard, Suzanne, et al.
Publicado: (2021)

Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management
por: Berger, Tamar, et al.
Publicado: (2021)

Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia
por: Ribeiro, Sara, et al.
Publicado: (2021)

Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors
por: Shacham Abulafia, Adi, et al.
Publicado: (2020)

Advances in the treatment of chronic myeloid leukemia
por: Eiring, Anna M, et al.
Publicado: (2011)

Neutrophil Extracellular Traps Are Increased in Chronic Myeloid Leukemia and Are Differentially Affected by Tyrosine Kinase Inhibitors
por: Telerman, Alona, et al.
Publicado: (2021)

A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia
por: Bolandi, Seyed Mohammadreza, et al.
Publicado: (2021)

Mr. Stables, on the Influenza
por: Stables, J.
Publicado: (1803)

Measurable residual disease in chronic myeloid leukemia
por: Branford, Susan, et al.
Publicado: (2022)

Lymphoid blast crisis after prolonged treatment‐free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de‐escalation during the COVID‐19 pandemic
por: Avenoso, Daniele, et al.
Publicado: (2021)

Consensus on BCR‐ABL1 reporting in chronic myeloid leukaemia in the UK
por: Cross, Nicholas C. P., et al.
Publicado: (2018)

Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients
por: Davies, Andrea, et al.
Publicado: (2020)

New concepts for CML clonality
por: Khorashad, Jamshid S., et al.
Publicado: (2013)

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib
por: Breccia, Massimo, et al.
Publicado: (2017)

Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations
por: Abruzzese, Elisabetta, et al.
Publicado: (2020)

Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival
por: Galleu, Antonio, et al.
Publicado: (2019)

Coexistence of two missense mutations in the KRAS gene in adenocarcinoma of the lung: a possible indicator of poor prognosis
por: Spinelli, Manuela, et al.
Publicado: (2022)

Omega-3 polyunsaturated fatty acids selectively inhibit growth in neoplastic oral keratinocytes by differentially activating ERK1/2
por: Nikolakopoulou, Zacharoula, et al.
Publicado: (2013)

Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia
por: Sears, D, et al.
Publicado: (2010)

A Review of Circulating Tumour Cell Enrichment Technologies
por: Rushton, Amelia J., et al.
Publicado: (2021)

RAPID CONVERSION OF CHRONIC MYELOID LEUKEMIA TO CHRONIC MYELOMONOCYTIC LEUKEMIA IN A PATIENT ON IMATINIB THERAPY
por: Khorashad, Jamshid S., et al.
Publicado: (2016)

An all-atom protein generative model
por: Chu, Alexander E., et al.
Publicado: (2023)

Regulation of myeloid leukemia by the cell fate determinant Musashi
por: Ito, Takahiro, et al.
Publicado: (2010)

Mode of clinical presentation and delayed diagnosis of Turner syndrome: a single Centre UK study
por: Apperley, Louise, et al.
Publicado: (2018)

Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
por: Hochhaus, Andreas, et al.
Publicado: (2020)

A Rare Case of Acute Bilateral Endothelial Decompensation after Prophylactic Nd:YAG Laser Iridotomy Requiring Endothelial Keratoplasty
por: Weill, Yishay, et al.
Publicado: (2020)

Effect of Opium Addiction on Aspirin Resistance in Stable Angina Pectoris
por: Forood, Afsaneh, et al.
Publicado: (2014)

Feasibly of CD24/CD11b as a Screening Test for Hematological Malignancies
por: Shapira, Shiran, et al.
Publicado: (2021)

Effect of Growth Hormone Therapy in Patients with Noonan Syndrome: A Retrospective Study
por: Apperley, Louise Jayne, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s93nro1nu3fnl7dmpcej7p4k8p